Drug intelligence / Profile preview

Hib conjugate vaccine (Vabiotech)

Development stage: Preclinical
Lead developer: Vabiotech
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

The Hib conjugate vaccine is a polysaccharide conjugate vaccine being developed by Vabiotech, a Vietnamese biopharmaceutical company, for the prevention of *Haemophilus influenzae* type b (Hib) infections in children. The vaccine consists of the Hib polysaccharide capsule antigen chemically linked to a carrier protein. This conjugation converts the T-cell-independent polysaccharide into a T-cell-dependent antigen, thereby inducing a more robust immune response and immunological memory in infants and young children. It is intended for use as a standalone product or as a component of a 5-in-1 combination vaccine.

Other names: Vắc xin Hib cộng hợpHib conjugate vaccine

Targets

PRNP (Cellular Prion Protein)

Beyond the preview

Go deeper on Hib conjugate vaccine (Vabiotech).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hib conjugate vaccine (Vabiotech).

Explore the full profile